JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Eli Lilly and Co.

Chiusa

SettoreSettore sanitario

765.52 -0.26

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

759.46

Massimo

769.31

Metriche Chiave

By Trading Economics

Entrata

-6.1B

2.8B

Vendite

-804M

13B

P/E

Media del settore

66.239

40.048

Rendimento da dividendi

0.66

Margine di Profitto

21.678

Dipendenti

47,000

EBITDA

-2B

4.2B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+33.78% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.66%

2.45%

Utili prossimi

7 ago 2025

Prossima data del Dividendo

10 set 2025

Prossima data del' Ex Dividendo

15 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-98B

730B

Apertura precedente

765.78

Chiusura precedente

765.52

Notizie sul Sentiment di mercato

By Acuity

60%

40%

331 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Eli Lilly and Co. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 giu 2025, 11:56 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

27 mag 2025, 14:41 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

30 lug 2025, 10:38 UTC

Discorsi di Mercato

Novo Nordisk Could Struggle to Regain Investors' Trust -- Market Talk

29 lug 2025, 17:05 UTC

Utili

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- 3rd Update

29 lug 2025, 16:55 UTC

Utili

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

29 lug 2025, 13:35 UTC

Utili

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- Update

29 lug 2025, 11:39 UTC

Utili

Novo Nordisk Stock Tumbles 20% After Ozempic Maker's Shock Cut to U.S. Outlook -- Barrons.com

25 lug 2025, 12:49 UTC

Acquisizioni, Fusioni, Takeovers

Lilly Completes Acquisition Of Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

24 lug 2025, 12:02 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly Expects to Complete Verve Acquisition on July 25 >LLY VERV

24 lug 2025, 12:01 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly: About 55.7% of Verve Shares Tendered >LLY VERV

24 lug 2025, 12:00 UTC

Acquisizioni, Fusioni, Takeovers

Lilly and Verve Announce Expiration of Verve Tender Offer

9 lug 2025, 09:17 UTC

Azioni calde

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

17 giu 2025, 14:02 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17 giu 2025, 12:12 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17 giu 2025, 11:01 UTC

Acquisizioni, Fusioni, Takeovers

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17 giu 2025, 10:47 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17 giu 2025, 10:47 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17 giu 2025, 10:46 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17 giu 2025, 10:45 UTC

Acquisizioni, Fusioni, Takeovers

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17 giu 2025, 09:33 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

11 giu 2025, 09:45 UTC

Discorsi di Mercato

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

29 mag 2025, 01:00 UTC

Notizie principali

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28 mag 2025, 18:09 UTC

Utili

Heart Disease Could Be a Goner When These New -2-

28 mag 2025, 18:09 UTC

Utili

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27 mag 2025, 14:02 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27 mag 2025, 14:01 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27 mag 2025, 14:00 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27 mag 2025, 14:00 UTC

Acquisizioni, Fusioni, Takeovers

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20 mag 2025, 14:08 UTC

Utili

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12 mag 2025, 22:14 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

Confronto tra pari

Modifica del prezzo

Eli Lilly and Co. Previsione

Obiettivo di Prezzo

By TipRanks

33.78% in crescita

Previsioni per 12 mesi

Media 1,028.8 USD  33.78%

Alto 1,190 USD

Basso 883 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Eli Lilly and Co. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

19 ratings

17

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

N/A / 884.54Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

331 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.